Importantly, like FBXW7, PPARA expression declines as NASH progresses and is significantly reduced in liver fibrosis, cirrhosis, and HCC, with low PPARA expression associated with a poor survival rate among HCC patients (Fig. 3g, h and Supplementary Fig. 3f–h). Here, PPARA is linked to metabolic dysfunction-associated steatohepatitis.